Litigation Details for Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)
Docket | ⤷ Sign Up | Date Filed | 2020-02-06 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:1 Patent Infringement | Assigned To | Maryellen Noreika |
Jury Demand | Referred To | ||
Patents | 7,390,791; 7,803,788; 8,754,065; 9,296,769 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Gilead Sciences, Inc. v. Apotex, Inc.
Details for Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2021-05-26 | 236 | Order - -Memorandum and Order | term of U.S. Patent Nos. 7,390,791 (“the ’791 Patent”) and 7,803,788 (“the ’788 Patent”) with agreed-upon…the two prodrug patents asserted in this case, U.S. Patent Nos. 7,390,791 and 7,803,788. …terms of U.S. Patent Nos. 8,754,065 (“the ’065 Patent”) and 9,296,769 (“the ’769 Patent”) are construed…the ’791 patent, which is incorporated by reference in the Hemi patents. (See ’065 patent at 1:16–… diastereomers” (’791 Patent – Claims 1, 4, 7, & 8; ’788 Patent – Claims 1– | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |